Alexander Sele

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 134 citations · Full text

Medicine, Oncology, Pharmacology +14

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas et al. · Clinical Cancer Research · 2017 · 118 citations

Medicine, Oncology, Pharmacology +13

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils et al. · Nature Communications · 2017 · 116 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

Denise Rageot, Thomas Bohnacker, Anna Melone et al. · Journal of Medicinal Chemistry · 2018 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Claudia Brandt, Petra Hillmann, Andreas Noack et al. · Neuropharmacology · 2018 · 80 citations

Medicine, Neuroscience, Pharmacology +15